Научные статьи \ Прикладные науки. Медицина. Технология \ Mедицинские науки \ Патология. Клиническая медицина \ Заболевания кроветворной системы, лимфатической системы и желез внутренней секреции. Эндокринные заболевания

Эпигенетические лекарства: новый рубеж в лечении сердечной недостаточности

Эпигенетические лекарства: новый рубеж в лечении сердечной недостаточности

Автор: Айтбаев К.А., Муркамилов И.Т., Муркамилова Ж.А., Фомин В.В., Кудайбергенова И.О., Юсупова Т.Ф., Юсупов Ф.А.

Журнал: Евразийский кардиологический журнал @eurasian-cardiology-journal

Рубрика: Обзор

Статья в выпуске: 4, 2023 года.

Бесплатный доступ

Раскрытие секретов гибкости генома не только способствовало развитию исследований в этой области, но также послужило толчком к разработке новых методов лечения болезней человека. Лучшее понимание биологии хроматина (комплексы ДНК/гистоны) и некодирующих РНК (нкРНК) позволило разработать эпигенетические (эпи) препараты, способные модулировать программы транскрипции, связанные с сердечно-сосудистыми заболеваниями. Это особенно относится к сердечной недостаточности, где было показано, что эпигенетические механизмы лежат в основе развития некоторых патологических процессов, таких как гипертрофия левого желудочка, фиброз, апоптоз кардиомиоцитов и дисфункция микрососудов. Ориентация на эпигенетические сигналы может представлять собой многообещающий подход, особенно у пациентов с сердечной недостаточностью с сохраненной фракцией выброса (СНсФВ), где прогноз остается неблагоприятным, а эффективных методов лечения пока не существует. В этих условиях эпигенетика может использоваться для разработки индивидуальных терапевтических подходов, что прокладывает путь к персонализированной медицине. Несмотря на то, что благоприятные эффекты эпи-препаратов привлекают всё большее внимание, количество эпигенетических соединений, используемых в клинической практике, остается низким, что свидетельствует о необходимости разработки более селективных эпи-препаратов. В настоящем обзоре мы приводим перечень новых перспективных эпи-препаратов для лечения сердечно-сосудистых заболеваний, с акцентом, главным образом, на СНсФВ. Терапевтический эффект этих препаратов обусловлен воздействием как минимум на один из трёх основных эпигенетических механизмов: метилирование ДНК, модификация гистонов и некодирующие РНК.

Еще

Сердечная недостаточность, эпи-терапия, персонализированная медицина

Короткий адрес: https://sciup.org/143181072

IDR: 143181072   |   УДК: 616.43   |   DOI: 10.38109/2225-1685-2023-4-76-82

Epigenetic drugs: a new frontier in the treatment of heart failure

Uncovering the secrets of genome flexibility not only contributed to the development of research in this area, but also served as an impetus for the development of new treatments for human diseases. A better understanding of the biology of chromatin (DNA/histone complexes) and non-coding RNAs (ncRNAs) has enabled the development of epigenetic (epi) preparations capable of modulating transcriptional programs associated with cardiovascular disease. This is especially true in heart failure, where epigenetic mechanisms have been shown to underlie the development of several pathological processes such as left ventricular hypertrophy, fibrosis, cardiomyocyte apoptosis, and microvascular dysfunction. Targeting epigenetic signals may represent a promising approach, especially in patients with heart failure with preserved ejection fraction (HFpEF), where the prognosis remains poor and effective treatments are not yet available. Under these conditions, epigenetics can be used to develop individualized therapeutic approaches, paving the way for personalized medicine. Although the beneficial effects of epi-drugs are gaining more attention, the number of epigenetic compounds used in clinical practice remains low, suggesting the need to develop more selective epi-drugs. In this review, we present a list of new promising epi-drugs for the treatment of cardiovascular diseases, with a focus mainly on HFpEF. The therapeutic effect of these drugs is due to the impact on at least one of the three main epigenetic mechanisms: DNA methylation, histone modification, and non-coding RNA.

Еще

Текст обзорной статьи Эпигенетические лекарства: новый рубеж в лечении сердечной недостаточности

Данная статья распространяется на условиях «открытого доступа», в соответствии с лицензией CC BY-NC-SA 4.0 («Attribution-NonCommercial-ShareAlike» / «Атрибуция-Не-коммерчески-Сохранение Условий» 4.0), которая разрешает неограниченное некоммерческое использование, распространение и воспроизведение на любом носителе при условии указания автора и источника. Чтобы ознакомиться с полными условиями данной лицензии на русском языке, посетите сайт: by-nc-sa/4.0/

UDC 616.43

Список литературы Эпигенетические лекарства: новый рубеж в лечении сердечной недостаточности

  • Weinhold B. Epigenetics: the science of change. Environ Health Perspect. 2006;114:A160–7. https://doi.org/10.1289/ehp.114-a160
  • Rozek LS, Dolinoy DC, Sartor MA, Omenn GS. Epigenetics: relevance and implications for public health. Annu Rev Public Health. 2014;35:105– 22. https://doi.org/10.1146/annurev-publhealth-032013-182513
  • Maunakea AK, Nagarajan RP, Bilenky M et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature. 2010;466:253–7. https://doi.org/10.1038/nature09165
  • Mohammed SA, Ambrosini S, Lüscher T et al. Epigenetic control of mitochondrial function in the vasculature. Front Cardiovasc Med. 2020;7:28. https://doi.org/10.3389/fcvm.2020.00028
  • Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011;123:2145–56. https://doi.org/10.1161/CIRCULATIONAHA.110.956839
  • Gao J, Shao K, Chen X et al. The involvement of post-translational modifications in cardiovascular pathologies: focus on SUMOylation, neddylation, succinylation, and prenylation. J Mol Cell Cardiol. 2020;138:49–58. https://doi.org/10.1016/j.yjmcc.2019.11.146
  • Das S, Shah R, Dimmeler S et al. Noncoding RNAs in cardiovascular disease: current knowledge, tools and technologies for investigation, and future directions: a scientific statement from the American heart association. Circ Genom Precis Med. 2020;13:e000062. https://doi.org/10.1161/HCG.0000000000000062
  • Zhong J, Agha G, Baccarelli AA. The role of DNA methylation in cardiovascular risk and disease. Circ Res. 2016;118:119–31. https://doi.org/10.1161/CIRCRESAHA.115.305206
  • Aggarwal R, Jha M, Shrivastava A, Jha AK. Natural compounds: role in reversal of epigenetic changes. Biochemistry. 2015;80:972–89. https://doi.org/10.1134/S0006297915080027
  • Ganesan A, Arimondo PB, Rots MG et al. The timeline of epigenetic drug discovery: from reality to dreams. Clin Epigenet. 2019;11:174. https://doi.org/10.1186/s13148-019-0776-0
  • Savarese G, Becher PM, Lund LH et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023 Jan 18;118(17):3272-3287. https://doi.org/10.1093/cvr/cvac013
  • Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023 Mar 14;329(10):827-838. https://doi.org/10.1001/jama.2023.2020
  • Skinner MK. Role of epigenetics in developmental biology and transgenerational inheritance. Birth Defects Res C Embryo Today. 2011;93:51–5. https://doi.org/10.1002/bdrc.20199
  • From AM, Leibson CL, Bursi F et al. Diabetes in heart failure: prevalence and impact on outcome in the population. Am J Med. 2006;119:591–9. https://doi.org/10.1016/j.amjmed.2006.05.024
  • Liu CF, Tang WHW. Epigenetics in cardiac hypertrophy and heart failure. Basic Transl Sci. 2019;4:976–93. https://doi.org/10.1016/j.jacbts.2019.05.011
  • Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;30:30–41. https://doi.org/10.1038/nrcardio.2010.165
  • Rich MW. Heart failure in the 21st century: a cardiogeriatric syndrome. J Gerontol A Biol Sci Med Sci. 2001;56:M88–96. https://doi.org/10.1093/gerona/56.2.M88
  • Backs J, Olson EN. Control of cardiac growth by histone acetylation/ deacetylation. Circ Res. 2006;98:15–24. https://doi.org/10.1161/01.RES.0000197782.21444.8f
  • Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004; 109:1580–9. doi:10.1161/01.CIR.0000120390.68287.BB
  • Hill JA, Olson EN, Biology M-L. Mechanisms of disease cardiac plasticity. N Engl J Med. 2008;58:1370–80. https://doi.org/10.1056/NEJMra072139
  • Duygu B, de Windt LJ, da Costa Martins PA. Targeting microRNAs in heart failure. Trends Cardiovasc Med. 2016;26:99–110. https://doi.org/10.1016/j.tcm.2015.05.008
  • Ganesan A. Multitarget drugs: an epigenetic epiphany. ChemMedChem. 2016;11:1227–41. https://doi.org/10.1002/cmdc.201500394
  • Madsen A, Höppner G, Krause J et al. An important role for DNMT3amediated DNA methylation in cardiomyocyte metabolism and contractility. Circulation. 2020;142:1562–78. https://doi.org/10.1161/CIRCULATIONAHA.119.044444
  • Stenzig J, Schneeberger Y, Löser A et al. Pharmacological inhibition of DNA methylation attenuates pressure overload-induced cardiac hypertrophy in rats. J Mol Cell Cardiol. 2018;120:53–63. https://doi.org/10.1016/j.yjmcc.2018.05.012
  • Gnyszka A, Jastrzebski Z, Flis S. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 2013;33:2989–96.
  • Fraineau S, Palii CG, Allan DS, Brand M. Epigenetic regulation of endothelial-cell-mediated vascular repair. FEBS J. 2015;282:1605–29. https://doi.org/10.1111/febs.13183
  • Plácido R, Heinonen IHA, Volpe M et al. Microvascular dysfunction in heart failure with preserved ejection fraction. Front Physiol. 2018;10:1347. https://doi.org/10.3389/fphys.2019.01347
  • Rajan A, Shi H, Xue B. Class I and II histone deacetylase inhibitors differentially regulate thermogenic gene expression in brown adipocytes open. Sci Rep. 2018;8:13072. https://doi.org/10.1038/s41598-018-31560-w
  • Napoli C, Benincasa G, Donatelli F, Ambrosio G. Precision medicine in distinct heart failure phenotypes: focus on clinical epigenetics. Am Heart J. 2020;224:113–28. https://doi.org/10.1016/j.ahj.2020.03.007
  • Wang Y, Miao X, Liu Y et al. Dysregulation of histone acetyltransferases and deacetylases in cardiovascular diseases. Oxid Med Cell Longev. 2014;2014:641979. https://doi.org/10.1155/2014/641979
  • Kong Y, Tannous P, Lu G et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation. 2006;113:2579–88. https://doi.org/10.1161/CIRCULATIONAHA.106.625467
  • Granger A, Abdullah I, Huebner F et al. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J.2008;22:3549–60. https://doi.org/10.1096/fj.08-108548
  • Xie M, Kong Y, Tan W et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation. 2014;129:1139–51. https://doi.org/10.1161/CIRCULATIONAHA.113.002416
  • Kee HJ, Sohn IS, Nam KI et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation. 2006 Jan 3;113(1):51-59. https://doi.org/10.1161/CIRCULATIONAHA.105.559724
  • Wallner M, Eaton DM, Berretta RM et al. HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction. Sci Transl Med. 2020;12:eaay7205. https://doi.org/10.1126/scitranslmed.aay7205
  • Testai L, Sestito S, Martelli A et al. Synthesis and pharmacological characterization of mitochondrial KATP channel openers with enhanced mitochondriotropic effects. Bioorgan Chem. 2021;107:104572. https://doi.org/10.1016/j.bioorg.2020.104572
  • Kelly WK, Marks P, Richon VM. CCR 20th anniversary commentary: vorinostat–gateway to epigenetic therapy. Clin Cancer Res. 2015;21:2198–200. https://doi.org/10.1158/1078-0432.CCR-14-2556
  • Ho TCS, Chan AHY, Ganesan A. Thirty years of HDAC inhibitors: 2020 insight and hindsight. J Med Chem Am Chem Soc. 2020;63:12460–84. https://doi.org/10.1021/acs.jmedchem.0c00830
  • Jeong MY, Lin YH, Wennersten SA et al. Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. Sci Transl Med. 2018;10:eaao0144. https://doi.org/10.1126/scitranslmed.aao0144
  • Gillette T.G. HDAC inhibition in the heart: erasing hidden fibrosis. Circulation.2021;143(19):1891-1893. https://doi.org/10.1161/CIRCULATIONAHA.121.054262
  • Travers JG, Wennersten SA, Peña B, Bagchi RA, Smith HE, Hirsch RA, McKinsey TA. HDAC inhibition reverses preexisting diastolic dysfunction and blocks covert extracellular matrix remodeling. Circulation.2021;143(19):1874-1890. https://doi.org/10.1161/CIRCULATIONAHA.120.046462
  • Mattson RH, Cramer JA, Williamson PD, Novelly RA. Valproic acid in epilepsy: clinical and pharmacological effects. Ann Neurol. 1978;3:20–5. https://doi.org/10.1002/ana.410030105
  • Mokhtarani M, Diaz GA, Rhead W et al. Urinary phenylacetylglutamine as dosing biomarker for patients with urea cycle disorders. Mol Genet Metab. 2012;107:308–14. https://doi.org/10.1016/j.ymgme.2012.08.006 44. Tian S, Lei I, Gao W et al. HDAC inhibitor valproic acid protects heart function through Foxm1 pathway after acute myocardial infarction. EBioMedicine. 2019;39:83–94. https://doi.org/10.1016/j.ebiom.2018.12.003
  • Subramanian U, Kumar P, Mani I et al. Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice. Physiol Genomics. 2016;48:477–90. https://doi.org/10.1152/physiolgenomics.00073.2015
  • Chan-Penebre E, Kuplast KG, Majer CR et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. Nat Chem Biol. 2015;11:432–7. https://doi.org/10.1038/nchembio.1810
  • Morera L, Lübbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenet. 2016;8:57. https://doi.org/10.1186/s13148-016-0223-4
  • Guo Y, Su Z-Y, Kong A-NT. Current perspectives on epigenetic modifications by dietary chemopreventive and herbal phytochemicals. Curr Pharmacol Rep. 2015;1:245–57. https://doi.org/10.1007/s40495-015-0023-0
  • Andrieu G, Belkina AC, Denis GV. Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today Technol. 2016;19:45–50. https://doi.org/10.1016/j.ddtec.2016.06.004
  • Kalow W. Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine. Pharmacogenomics J. 2006;6:162–5. https://doi.org/10.1038/sj.tpj.6500361
  • Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell Cell Press. 2014;54:728–36. https://doi.org/10.1016/j.molcel.2014.05.016
  • Borck PC, Guo LW, Plutzky J. BET epigenetic reader proteins in cardiovascular transcriptional programs. Circ Res. 2020;126:1190–208. https://doi.org/10.1161/CIRCRESAHA.120.315929
  • Nicholls SJ, Ray KK, Johansson JO et al. Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs. 2018;18:109–15. https://doi.org/10.1007/s40256-017-0250-3
  • Nicholls SJ, Schwartz GG, Buhr KA et al. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol. 2021;20:13. https://doi.org/10.1186/s12933-020-01199-x
  • Tsujikawa LM, Fu L, Das S et al. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clin Epigenet. 2019;11:102. https://doi.org/10.1186/s13148-019-0696-z
  • Brandts J, Ray KK. Apabetalone – BET protein inhibition in cardiovascular disease and type 2 diabetes. Future Cardiol. 2020;16:385–95. https://doi.org/10.2217/fca-2020-0017
  • Chioccioli M, Roy S, Rigby K et al. A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. bioRxiv [Preprint]. 2021. https://doi.org/10.1101/2021.12.22.473724
  • van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. 2008;105:13027–32. https://doi.org/10.1073/pnas.0805038105
  • Landmesser U, Poller W, Tsimikas S et al. From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. Eur Heart J. 2020;41:3884–99. https://doi.org/10.1093/eurheartj/ehaa229
  • Gargiulo P, Marzano F, Salvatore M, et al. MicroRNAs: diagnostic, prognostic and therapeutic role in heart failure — a review. ESC Heart Failure. 2023;10:2:753-761. https://doi.org/10.1002/ehf2.14153
  • Ruan W, Zhao F, Zhao S et al. Knockdown of long noncoding RNA MEG3 impairs VEGF-stimulated endothelial sprouting angiogenesis via modulating VEGFR2 expression in human umbilical vein endothelial cells. Gene. 2018;649:32–9. https://doi.org/10.1016/j.gene.2018.01.072
  • Leisegang MS, Fork C, Josipovic I et al. Long noncoding RNA MANTIS facilitates endothelial angiogenic function. Circulation. 2017;136:65–79. https://doi.org/10.1161/CIRCULATIONAHA.116.026991
  • Man HSJ, Sukumar AN, Lam GC et al. Angiogenic patterning by STEEL, an endothelial-enriched long noncoding RNA. Proc Natl Acad Sci USA. 2018;115:2401–6. https://doi.org/10.1073/pnas.1715182115
  • Zhang X, Tang X, Hamblin MH, Yin K-J. Long non-coding RNA malat1 regulates angiogenesis in hindlimb ischemia. Int J Mol Sci. 2018; 19:1723. doi:10.3390/ijms19061723
  • Simion V, Haemmig S, Feinberg MW. LncRNAs in vascular biology and disease. Vasc Pharmacol. 2019;114:145–56. https://doi.org/10.1016/j.vph.2018.01.003
  • Miano JM, Zheng D, Bell RD et al. Identification and initial functional characterization of a human vascular cell-enriched long noncoding RNA. Arterioscler Thromb Vasc Biol. 2014;34:1249–59. https://doi.org/10.1161/ATVBAHA.114.303240
  • Vance KW, Schulte C, Thum T et al. Long non-coding RNAs: at the heart of cardiac dysfunction? Front Physiol. 2019;10:30. https://doi.org/10.3389/fphys.2019.00030
  • Zhou W, Wang C, Chang J et al. RNA methylations in cardiovascular diseases, molecular structure, biological functions and regulatory roles in cardiovascular diseases. Front Pharmacol. 2021;12:722728. https://doi.org/10.3389/fphar.2021.722728
  • Qin Y, Li L, Luo E et al. Role of m6A RNA methylation in cardiovascular disease (review). Int J Mol Med. 2020;46:1958–72. https://doi.org/10.3892/ijmm.2020.4746
  • Zhang B, Xu Y, Cui X et al. Alteration of m6A RNA methylation in heart failure with preserved ejection fraction. Front Cardiovasc Med. 2021;8:647806. https://doi.org/10.3389/fcvm.2021.647806
  • Cao M, Luo H, Li D et al. Research advances on circulating long noncoding RNAs as biomarkers of cardiovascular diseases. Int J Cardiol. 2022;353:109–17. https://doi.org/10.1016/j.ijcard.2022.01.070
Еще
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp